(Q34355555)

1 August 2017

title

Generation of a parvovirus B19 vaccine candidate (English)

1 reference

1 August 2017

0 references

1

Sumana Chandramouli

1 reference

1 August 2017

11

Philip R Dormitzer

1 reference

1 August 2017

author name string

Angelica Medina-Selby

2

1 reference

1 August 2017

Doris Coit

3

1 reference

1 August 2017

Mary Schaefer

4

1 reference

1 August 2017

Terika Spencer

5

1 reference

1 August 2017

Luis A Brito

6

1 reference

1 August 2017

Pu Zhang

7

1 reference

1 August 2017

Gillis Otten

8

1 reference

1 August 2017

Christian W Mandl

9

1 reference

1 August 2017

Peter W Mason

10

1 reference

1 August 2017

Ethan C Settembre

12

1 reference

1 August 2017

language of work or name

English

0 references

publication date

2 July 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

31

1 reference

1 August 2017

issue

37

1 reference

1 August 2017

page(s)

3872-3878

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

1 August 2017

1 reference

An outbreak of erythema infectiosum associated with human parvovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Epidemiology of human parvovirus B19 in children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Congenital anaemia after transplacental B19 parvovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Immune response to B19 parvovirus and an antibody defect in persistent viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Risk factors for parvovirus B19 infection in pregnancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Candidate recombinant vaccine for human B19 parvovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

A viral phospholipase A2 is required for parvovirus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Characterization and Molecular Cloning of a Human Parvovirus Genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Development of an improved method of detection of infectious parvovirus B19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Production and immunological analysis of recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Visualization of the externalized VP2 N termini of infectious human parvovirus B19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.062

10.1016/J.VACCINE.2013.06.062

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference